Trade PTGX stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Protagonist Therapeutics, Inc. (PTGX) is trading at US$143.00, down 0.49% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$9.99B. Over the past 52 weeks, PTGX has traded between US$61.95 and US$160.81. On Syfe you can trade PTGX with $0 commission and add it to your watchlist.
| Previous close | US$143.70 |
|---|---|
| Market cap | US$9.99B |
| P/E ratio | 150.28 |
| 52-week range | US$61.95 – US$160.81 |
| Volume | 1.82M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Year: 2016
Protagonist Therapeutics Insider Sold Shares Worth $14,890,799, According to a Recent SEC Filing
Aug 13, 8:04 AM · MT Newswires
Protagonist Therapeutics, Inc. (PTGX) stock is trading at US$143.00, -0.49% from the previous close of US$143.70.
The market cap for Protagonist Therapeutics, Inc. (PTGX) stock is approximately US$9.99B.
The price-to-earnings ratio for Protagonist Therapeutics, Inc. (PTGX) is 150.28, based on the latest reported earnings.
The 52-week high for Protagonist Therapeutics, Inc. (PTGX) stock is US$160.81.
The 52-week low for Protagonist Therapeutics, Inc. (PTGX) stock is US$61.95.
Protagonist Therapeutics, Inc. (PTGX) does not currently pay a dividend.
Stay on top of PTGX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
